MXPA04006517A - Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores. - Google Patents

Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.

Info

Publication number
MXPA04006517A
MXPA04006517A MXPA04006517A MXPA04006517A MXPA04006517A MX PA04006517 A MXPA04006517 A MX PA04006517A MX PA04006517 A MXPA04006517 A MX PA04006517A MX PA04006517 A MXPA04006517 A MX PA04006517A MX PA04006517 A MXPA04006517 A MX PA04006517A
Authority
MX
Mexico
Prior art keywords
tumours
fibronectin
treatment
domain
conjugates
Prior art date
Application number
MXPA04006517A
Other languages
English (en)
Inventor
Neri Giovanni
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of MXPA04006517A publication Critical patent/MXPA04006517A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Abstract

La presente invencion se refiere a metodos novedoso para diagnostico y tratamiento de tumores, utilizando peptidos novedosos para ligar radionuclidos.
MXPA04006517A 2002-01-03 2003-01-02 Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores. MXPA04006517A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02000315 2002-01-03
US35870202P 2002-02-25 2002-02-25
PCT/EP2003/000009 WO2003055917A2 (en) 2002-01-03 2003-01-02 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Publications (1)

Publication Number Publication Date
MXPA04006517A true MXPA04006517A (es) 2005-03-31

Family

ID=26077560

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006517A MXPA04006517A (es) 2002-01-03 2003-01-02 Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.

Country Status (15)

Country Link
US (1) US20040001790A1 (es)
EP (2) EP1461360B1 (es)
JP (2) JP2005523887A (es)
CN (1) CN1612895B (es)
AU (1) AU2003210149B2 (es)
BR (1) BR0306715A (es)
CA (1) CA2468081A1 (es)
CY (1) CY1110923T1 (es)
HK (1) HK1076474A1 (es)
IL (2) IL162201A0 (es)
MX (1) MXPA04006517A (es)
NO (1) NO20043246L (es)
PL (1) PL369371A1 (es)
RU (1) RU2352582C2 (es)
WO (1) WO2003055917A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) * 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
WO2001062800A1 (en) 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
JP2004529848A (ja) * 2000-09-07 2004-09-30 シエーリング アクチエンゲゼルシャフト ＥＤｂ−フィブロネクチンドメイン（ＩＩ）の受容体
ATE452912T1 (de) * 2002-03-11 2010-01-15 Philogen Spa Antikörper aus anti-ed-b l19 gerichtet auf tumorblutgefässe
EP1514561A1 (en) * 2003-09-10 2005-03-16 Philogen S.p.A. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
DE10348319A1 (de) * 2003-10-17 2005-05-19 Schering Ag Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
ATE374367T1 (de) * 2004-07-22 2007-10-15 Bayer Schering Pharma Ag Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind
US20060039863A1 (en) * 2004-07-22 2006-02-23 Michael Schirner Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ES2291071B1 (es) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
CA2650953A1 (en) * 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
KR101515243B1 (ko) * 2007-04-02 2015-04-24 필로겐 에스.피.에이. 종양 전이암의 신생혈관과 관련된 피브리노겐의 ｅｄ―ａ 항원
EP2036576A1 (en) * 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B fibronectin as stratification marker for antitumor drugs
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
RU2565402C2 (ru) 2009-07-22 2015-10-20 Актиниум Фармасьютикалз Инк. Способы получения радиоиммуноконъюгатов
EP2518086A1 (en) * 2009-12-25 2012-10-31 Riken Radiolabeled compound directable in vivo to target tissue and use thereof
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
CN104215668A (zh) * 2014-08-25 2014-12-17 浙江大学 基于theed纤维阵列的二氧化碳传感器及其制备方法
CN108291915B (zh) * 2015-11-16 2021-01-05 合肥立方制药股份有限公司 Ed-b蛋白在诊断组织增生中的应用
IL266112B1 (en) * 2016-10-17 2024-03-01 Pfizer Antibodies against EDB and antibody-drug conjugates
EP4153232A1 (en) 2020-05-22 2023-03-29 Philogen S.p.A. Tnf? immunoconjugate therapy for the treatment of brain tumors
KR20240034234A (ko) 2021-07-14 2024-03-13 2세븐티 바이오, 인코포레이티드 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2065299C (en) * 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
EP1997894B1 (en) * 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US6171578B1 (en) * 1999-04-14 2001-01-09 Diatide, Inc. Benzodiazepine derivatives for imaging thrombi
EP1185559A2 (en) * 1999-04-28 2002-03-13 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
WO2001062800A1 (en) 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis

Also Published As

Publication number Publication date
IL162201A0 (en) 2005-11-20
HK1076474A1 (en) 2006-01-20
RU2352582C2 (ru) 2009-04-20
CN1612895B (zh) 2010-05-12
IL162201A (en) 2011-04-28
CN1612895A (zh) 2005-05-04
JP4663020B2 (ja) 2011-03-30
WO2003055917A3 (en) 2003-12-24
WO2003055917A2 (en) 2003-07-10
RU2004123785A (ru) 2005-08-10
AU2003210149B2 (en) 2008-10-09
CY1110923T1 (el) 2015-06-10
JP2009209149A (ja) 2009-09-17
PL369371A1 (en) 2005-04-18
US20040001790A1 (en) 2004-01-01
JP2005523887A (ja) 2005-08-11
CA2468081A1 (en) 2003-07-10
EP1461360B1 (en) 2010-08-18
AU2003210149A1 (en) 2003-07-15
BR0306715A (pt) 2004-12-28
NO20043246L (no) 2004-08-02
EP2239274A1 (en) 2010-10-13
EP1461360A2 (en) 2004-09-29

Similar Documents

Publication Publication Date Title
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
IL244803B (en) Human anti-beta antibodies and their use
UA92505C2 (ru) Композиции на основе антитела против cd3
NO20060843L (no) RG1-antistoffer og anvendelser derav
RS80704A (en) ANTI- av?6.ANTIBODIES
DK1472541T3 (da) Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
WO2005103081A3 (en) Human monoclonal antibodies against cd20
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
MX2007011064A (es) Anticuerpos contra cd38 para tratamiento de mieloma multiple.
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
SG170793A1 (en) Anti-mn antibodies and methods of using same
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
MX2010007357A (es) Puesta de anti-cuerpos en objetivo mediante un dominio de reconocimiento modular.
UA109633C2 (uk) Антитіло людини проти тканинного фактора
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen
SI1461360T1 (sl) Konjugati, ki obsegajo protitelo, specifično za domeno ED-B fibronektina, in njihova uporaba za detekcijo in zdravljenje tumorjev
ATE230761T1 (de) Monoklonale antikörper gegen einen komplex aus humanem act und einer serinprotease
CY1115000T1 (el) Ανθρωπινα αντισωματα εναντια στη λυσσα και χρησεις αυτων
ATE490981T1 (de) Criptospezifische antikörper

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status